secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2021-10-29T23:59:59+00:00
Accession:  0001193125-21-313502
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Inovio loses AstraZeneca-partnered cancer vaccine pact; reacquires INO-3112 rights
--------------------------------------------------------------------------------

- MedImmune (AstraZeneca R&D) terminated INO-3112/MEDI0457 collaboration effective Oct 28, 2021.
- Inovio reacquires all rights to INO-3112; forfeits future milestone payments and royalties.
- MedImmune continues Phase 2 HNSCC trial; final data cut-off completed, study report by end of 2022.
- Revenue from the agreement was minimal: $33k in H1 2021, $171k in 2020, $2M in 2019.
- Company states it is not substantially dependent on the terminated collaboration agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/0001193125-21-313502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312521313502/d254133d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-313502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer